EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(3), P. 492 - 542

Published: June 7, 2024

Language: Английский

---

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Gut, Journal Year: 2024, Volume and Issue: unknown, P. gutjnl - 330595

Published: Jan. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Language: Английский

---

Can we use old NAFLD data under the new MASLD definition?

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(2), P. e54 - e56

Published: Aug. 2, 2023

Language: Английский

---

Alcohol-associated liver disease

Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(3)

Published: Feb. 1, 2024

Alcohol-associated liver disease (ALD) is a major cause of chronic worldwide, and comprises spectrum several different disorders, including simple steatosis, steatohepatitis, cirrhosis, superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field ALD over last 20 years, pathogenesis remains obscure, there are currently no FDA-approved drugs for treatment ALD. In this Review, we discuss new insights into therapeutic targets ALD, utilizing study multiomics other cutting-edge approaches. The potential translation these studies clinical practice therapy deliberated. We also preclinical models interplay metabolic dysfunction, alcohol-associated cancer, heterogeneity some translational research prospects

Language: Английский

---

HIV infection

Nature Reviews Disease Primers, Journal Year: 2023, Volume and Issue: 9(1)

Published: Aug. 17, 2023

Language: Английский

---

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 21(1), P. 46 - 56

Published: Oct. 5, 2023

Language: Английский

---

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 764 - 783

Published: Aug. 15, 2023

Language: Английский

---

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus

Nature Reviews Endocrinology, Journal Year: 2023, Volume and Issue: 20(1), P. 27 - 49

Published: Oct. 16, 2023

Language: Английский

---

National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature

Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 666 - 673

Published: Sept. 20, 2023

Background and Aims: The multisociety consensus nomenclature has renamed NAFLD to steatotic liver disease (SLD) with various subclassifications. There is a paucity of data regarding how the new modifies our understanding prevalence patient phenotypes. Approach Results: Using National Health Nutrition Examination Survey from January 2017 March 2020, we included all participants aged 18 years or above complete vibration-controlled transient elastography measures. SLD its subclassifications [metabolic dysfunction-associated (MASLD), MASLD + increased alcohol intake (MetALD), alcohol-associated (ALD), etiology-specific/cryptogenic] were defined according nomenclature. estimated, among key subgroups [age, sex, race/ethnicity, advanced fibrosis (liver stiffness measurement [LSM] ≥11.7 kPa)]. Among 7367 participants, 2549 had (mean age 51 y, 57.7% male, 63.2% non-Hispanic White). estimated was 34.2% (95% CI 31.9%–36.5%): 31.3% (29.2%–33.4%), MetALD 2% (1.6%–2.9%), ALD 0.7% (0.5–0.9%), etiology-specific/cryptogenic 0.03% (0.01%–0.08%). In exploratory analyses, classified as non-SLD (vs. without) higher mean number metabolic risk factors [2.7 (2.3–3.1) vs. 2.0 (1.9–2.0)] proportion average use ≥20 g/d (women)/≥30 (men) [20.9% (6.2%–51.3%) 7.2% (6.1%–8.4%)]. another analysis, increasing quantities remaining below threshold for associated in men, but not women. 99% overlap cases MASLD. Conclusions: Our findings highlight utility address deficiencies present old nomenclature, identify areas that require research further refine classifications SLD.

Language: Английский

---

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges

Metabolism, Journal Year: 2024, Volume and Issue: 154, P. 155835 - 155835

Published: March 19, 2024

Language: Английский

---